Results 11 to 20 of about 8,965 (175)

Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report a case evaluating PDT and eplerenone therapy in a patient with bilateral bullous central serous chorioretinopathy. Observations: A 30-year-old male was referred for worsening bilateral bullous central serous chorioretinopathy (bCSCR ...
William J. Anderson, Bradley T. Smith
doaj   +1 more source

Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats [PDF]

Diabetes & Metabolism Journal, 2012
BackgroundAldosterone antagonists are reported to have beneficial effects on diabetic nephropathy by effective blocking of the renin-angiotensin-aldosterone system.
Jae Hee Ahn, Ho Cheol Hong, Myong Jin Cho, Yoon Jung Kim, Hae Yoon Choi, Chai Ryoung Eun, Sae Jeong Yang, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim   +14 more
doaj   +1 more source

Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy

Scientific Reports, 2022
To compare the anatomical/functional changes after navigated subthreshold pulse laser (SML) and oral eplerenone therapy for chronic central serous chorioretinopathy (cCSC). A total of 36 eyes of 36 patients suffering from cCSC treated with navigated SML (
Lisa Toto, Rossella D’Aloisio, Chiara De Nicola, Federica Evangelista, Maria Ludovica Ruggeri, Luca Cerino, Maria Beatrice Simonelli, Agbéanda Aharrh-Gnama, Marta Di Nicola, Annamaria Porreca, Rodolfo Mastropasqua   +10 more
doaj   +1 more source

Eplerenone for hypertension [PDF]

Cochrane Database of Systematic Reviews, 2011
Eplerenone is an aldosterone receptor blocker that is chemically derived from spironolactone. In Canada, it is indicated for use as adjunctive therapy to reduce mortality for heart failure patients with New York Heart Association (NYHA) class II systolic chronic heart failure and left ventricular systolic dysfunction.
Tina Sc, Tam, May Hy, Wu, Sarah C, Masson, Matthew P, Tsang, Sarah N, Stabler, Angus, Kinkade, Anthony, Tung, Aaron M, Tejani   +7 more
openaire   +2 more sources

The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus

Бюллетень сибирской медицины, 2021
Aim. To study the effect of eplerenone on the activity of free radical oxidation and renal function in rats with experimental diabetes mellitus induced by streptozotocin.Materials and methods. Experiments were carried out on 36 male Wistar rats. Diabetes
A. Yu. Zharikov, S. O. Filinova, O. N. Mazko, O. G. Makarova, I. P. Bobrov, V. M. Bryukhanov   +5 more
doaj   +1 more source

Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats

Clinical and Experimental Hypertension, 2020
Evidence indicates that renin-angiotensin-aldosterone system (RAS) inhibitors can protect the brain in Alzheimer’s disease and Parkinson’s disease.
Xue Wang, Yuhai Zhu, Shuanglin Wang, Zhuoqun Wang, Haonan Sun, Yujie He, Wei Yao   +6 more
doaj   +1 more source

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)

Лечащий Врач, 2023
The article focuses on the negative role of hyperaldosteronism in cardiovascular diseases and the possibility of its control when using a selective mineralocorticoid receptor antagonist – eplerenone.
A. G. Evdokimova, R. I. Stryuk, V. V. Evdokimov, A. K. Kaptaeva   +3 more
doaj   +1 more source

Possible dose-dependent effect of eplerenone on intraocular pressure

Indian Journal of Ophthalmology, 2023
Purpose: Intraocular pressure (IOP) is the main modifiable risk factor for glaucoma. Current therapies target the anterior outflow of aqueous humor or its production. This study aims to demonstrate eplerenone could reduce IOP through a possible posterior
Seyedeh Mehrsa Sadat Razavi, Ramin Daneshvar   +1 more
doaj   +1 more source

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE

Кардиоваскулярная терапия и профилактика, 2015
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj   +1 more source

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE

Рациональная фармакотерапия в кардиологии, 2015
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
B. B. Gegenava, O. M. Drapkina
doaj   +3 more sources